Navigating ethics in the large grey zone of unproven stem cell treatments
To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.
EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.
You can now read the lay summary for the article entitled, “Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation” from Sarah Chan .
Ethical and safety concerns are being raised about the increasing number of clinics marketing unproven stem cell therapies around the world. Addressing these issues requires understanding both the scope of what unproven treatments are and how clinics offering these therapies fit into the broader picture of regenerative medicine translation at the interface of research, health care, commercial markets and government policy.
What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here: https://www.eurostemcell.org/regenerative-medicine-society/navigating-ethics-large-grey-zone-unproven-stem-cell-treatments
The full original article can be accessed here: https://www.futuremedicine.com/doi/10.2217/rme-2017-0065
 Chan S. Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation. Regen. Med. 12(7), 839–851 (2017).